OBJECTIVES: In preparation for a pediatric randomized controlled trial on thromboprophylaxis, we determined the frequency of catheter-related thrombosis in children. We also systematically reviewed the pediatric trials on thromboprophylaxis to evaluate its efficacy and to identify possible pitfalls in the conduct of these trials. PATIENTS/ METHODS: We searched MEDLINE, EMBASE, Web of Science and the Cochrane Central Register for Controlled Trials for articles published until December 2013. We included cohort studies and trials on patients aged 0-18 years with central venous catheters who underwent active surveillance for thrombosis with radiologic imaging. We estimated the pooled frequency of thrombosis and the pooled risk ratio (RR) with thromboprophylaxis by using a random effects model. RESULTS: From 2651 articles identified, we analyzed 37 articles with 3128 patients. The pooled frequency of thrombosis was 0.20 (95% confidence interval [CI] 0.16-0.24). In 10 trials, we did not find evidence that heparin-bonded catheters (RR 0.34; 95%CI 0.01-7.68), unfractionated heparin (RR 0.93; 95% CI 0.57-1.51), low molecular weight heparin (RR 1.13; 95% CI 0.51-2.50), warfarin (RR 0.85; 95%CI 0.34-2.17), antithrombin concentrate (RR 0.76; 95% CI 0.38-1.55) or nitroglycerin (RR 1.53; 95%CI 0.57-4.10) reduced the risk of thrombosis. Most of the trials were either not powered for thrombosis or were powered to detect large, probably unachievable, reductions in thrombosis. Missing data on thrombosis also limited these trials. CONCLUSIONS: Catheter-related thrombosis is common in children. An adequately powered multicenter trial that can detect a modest, clinically significant reduction in thrombosis is critically needed. Missing outcome data should be minimized in this trial.
OBJECTIVES: In preparation for a pediatric randomized controlled trial on thromboprophylaxis, we determined the frequency of catheter-related thrombosisin children. We also systematically reviewed the pediatric trials on thromboprophylaxis to evaluate its efficacy and to identify possible pitfalls in the conduct of these trials. PATIENTS/ METHODS: We searched MEDLINE, EMBASE, Web of Science and the Cochrane Central Register for Controlled Trials for articles published until December 2013. We included cohort studies and trials on patients aged 0-18 years with central venous catheters who underwent active surveillance for thrombosis with radiologic imaging. We estimated the pooled frequency of thrombosis and the pooled risk ratio (RR) with thromboprophylaxis by using a random effects model. RESULTS: From 2651 articles identified, we analyzed 37 articles with 3128 patients. The pooled frequency of thrombosis was 0.20 (95% confidence interval [CI] 0.16-0.24). In 10 trials, we did not find evidence that heparin-bonded catheters (RR 0.34; 95%CI 0.01-7.68), unfractionated heparin (RR 0.93; 95% CI 0.57-1.51), low molecular weight heparin (RR 1.13; 95% CI 0.51-2.50), warfarin (RR 0.85; 95%CI 0.34-2.17), antithrombin concentrate (RR 0.76; 95% CI 0.38-1.55) or nitroglycerin (RR 1.53; 95%CI 0.57-4.10) reduced the risk of thrombosis. Most of the trials were either not powered for thrombosis or were powered to detect large, probably unachievable, reductions in thrombosis. Missing data on thrombosis also limited these trials. CONCLUSIONS: Catheter-related thrombosis is common in children. An adequately powered multicenter trial that can detect a modest, clinically significant reduction in thrombosis is critically needed. Missing outcome data should be minimized in this trial.
Authors: R Knöfler; E Siegert; I Lauterbach; H Taut-Sack; G Siegert; S Gehrisch; D Müller; E Rupprecht; M Kabus Journal: Eur J Pediatr Date: 1999-12 Impact factor: 3.183
Authors: Manuela Bonizzoli; Stefano Batacchi; Giovanni Cianchi; Giovanni Zagli; Francesco Lapi; Valentina Tucci; Giacomo Martini; Simona Di Valvasone; Adriano Peris Journal: Intensive Care Med Date: 2010-09-21 Impact factor: 17.440
Authors: Luis Asmarats; Carlos Fernández-Palomeque; Juan Manuel Martínez-Riutort; Armando Bethencourt Journal: J Thromb Thrombolysis Date: 2015-02 Impact factor: 2.300
Authors: Katharina Thom; Anthonie W A Lensing; Ildar Nurmeev; Fanny Bajolle; Damien Bonnet; Gili Kenet; M Patricia Massicotte; Zeynep Karakas; Joseph S Palumbo; Paola Saracco; Pascal Amedro; Juan Chain; Anthony K Chan; Takanari Ikeyama; Joyce C M Lam; Cynthia Gauger; Ákos Ferenc Pap; Madhurima Majumder; Dagmar Kubitza; William T Smith; Scott D Berkowitz; Martin H Prins; Paul Monagle; Guy Young; Christoph Male Journal: Blood Adv Date: 2020-10-13
Authors: Simon Li; Cicero T Silva; Adele R Brudnicki; Kenneth E Baker; Joana A Tala; Matthew G Pinto; Lee A Polikoff; Li Qin; E Vincent S Faustino Journal: Pediatr Radiol Date: 2015-10-06
Authors: E Vincent S Faustino; Veronika Shabanova; Leslie J Raffini; Sarah B Kandil; Simon Li; Matthew G Pinto; Jill M Cholette; Sheila J Hanson; Marianne E Nellis; Cicero T Silva; Ranjit Chima; Anjali Sharathkumar; Kimberly A Thomas; Tara McPartland; Joana A Tala; Philip C Spinella Journal: Crit Care Med Date: 2021-03-01 Impact factor: 9.296
Authors: E Vincent S Faustino; Leslie J Raffini; Sheila J Hanson; Jill M Cholette; Matthew G Pinto; Simon Li; Sarah B Kandil; Marianne E Nellis; Veronika Shabanova; Cicero T Silva; Joana A Tala; Tara McPartland; Philip C Spinella Journal: Crit Care Med Date: 2021-04-01 Impact factor: 9.296